Adam A. Dalia
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Adam A. Dalia.
Seminars in Cardiothoracic and Vascular Anesthesia | 2017
Adam A. Dalia; Hisham Khan; Antolin S. Flores
Anesthesia for orthotopic liver transplantation (OLT) is challenging for any anesthesiologist as the patients undergoing this procedure are among the most critically ill. Adding to the underlying complexity of OLT management is the rare complication of an intracardiac thrombus (ICT). Intracardiac thrombi can present following liver allograft reperfusion resulting in high morbidity and mortality. Currently there is no consensus treatment for ICT, and the gold standard for diagnosis is intraoperative transesophageal echocardiography (TEE); these 2 factors lead to a dangerous amalgam of the difficulty in diagnosing and treating the disease. We describe 2 separate cases in detail of ICT formation during OLT that were recognized and diagnosed with intraoperative TEE. These 2 cases highlight the important role of TEE in the management of ICT. A thorough literature review that follows analyzes our current understanding of ICT during OLT and the vital function of TEE by every anesthesiologists regardless of formal TEE training. Broader use of TEE during all OLTs can help narrow the anesthesiologist’s differential diagnosis during the acute phases of transplantation and should be considered in all liver transplant surgeries.
Frontiers of Medicine in China | 2016
Michael Essandoh; Andrew J. Otey; Adam A. Dalia; Elisabeth Dewhirst; Andrew Springer; Mitchell Henry
Hypotension after reperfusion is a common occurrence during liver transplantation following the systemic release of cold, hyperkalemic, and acidic contents of the liver allograft. Moreover, the release of vasoactive metabolites such as inflammatory cytokines and free radicals from the liver and mesentery, compounded by the hepatic uptake of blood, may also cause a decrement in systemic perfusion pressures. Thus, the postreperfusion syndrome (PRS) can materialize if hypotension and fibrinolysis occur concomitantly within 5 min of reperfusion. Treatment of the PRS may require the administration of inotropes, vasopressors, and intravenous fluids to maintain hemodynamic stability. However, the occurrence of the PRS and its treatment with inotropes and calcium chloride may lead to dynamic left ventricular outflow tract obstruction (DLVOTO) precipitating refractory hypotension. Expedient diagnosis of DLVOTO with transesophageal echocardiography is extremely vital in order to avoid potential cardiovascular collapse during this critical period.
Journal of Cardiothoracic and Vascular Anesthesia | 2017
Michael Essandoh; Adam A. Dalia; Mazen Albaghdadi; Barry S. George; Nicoleta Stoicea; Muhammad Shabsigh; Sunil V. Rao
Dual-antiplatelet therapy (DAPT) is considered mandatory after new-generation drug-eluting coronary stent implantation to reduce ischemic complications such as stent thrombosis, but the need for DAPT makes the timing of elective surgery difficult. Interrupting DAPT places patients at risk for stent thrombosis, and surgery in the setting of DAPT may lead to bleeding. The 2016 American College of Cardiology/American Heart Association guideline recommends delaying elective noncardiac surgery for a minimum 6-month period to reduce ischemic risks after the implantation of a second-generation metallic drug-eluting stent (DES). However, the guideline fails to appropriately stratify surgical patients based on the indication for second-generation metallic DES implantation and other patient characteristics. The Absorb bioresorbable vascular scaffold (Abbott Vascular, Abbott Park, IL), which has a higher propensity for stent thrombosis compared with second-generation metallic DES, also produces DAPT management challenges in patients presenting for elective noncardiac surgery. Due to the novelty of bioresorbable vascular scaffold therapy, there are no guidelines available for the management of patients undergoing elective noncardiac surgery. This review addresses DAPT management in patients undergoing noncardiac surgery less than 12 months after new-generation metallic DES or bioresorbable vascular scaffold implantation and provides further guidance for anesthesiologists who encounter these challenging cases.
Seminars in Cardiothoracic and Vascular Anesthesia | 2018
Adam A. Dalia; Michael Essandoh
The MitraClip is a percutaneously implanted device approved for the treatment of symptomatic organic mitral regurgitation in poor surgical candidates. Despite its proven efficacy and safety for mitral regurgitation treatment, the MitraClip may unmask the true afterload of the left ventricle by removing the low-pressure left atrial system and may cause acute left ventricular systolic failure (afterload mismatch). Rapid diagnosis and treatment of afterload mismatch is crucial to ensure optimal patient outcomes. The authors present a case of acute hemodynamic deterioration after MitraClip implantation in a patient with chronic severe left ventricular systolic dysfunction. Transesophageal echocardiography was pivotal for the rapid recognition of acute left ventricular failure and aided in the intraoperative decision-making process and therapy.
Journal of Cardiothoracic and Vascular Anesthesia | 2018
Adam A. Dalia; Caroline Hunter; Elliot Woodward; David M. Dudzinski; Michael J. Andritsos; Michael Essandoh; Michael N. Andrawes
TECHNOLOGIES REGARDING SURGICAL TREATMENT of aortic stenosis have advanced rapidly over the past decade, evolving from standard open surgical aortic valve replacement (SAVR) to percutaneous transcatheter aortic valve replacement (TAVR) approaches. A novel approach to SAVR is the implantation of the sutureless Perceval (LivaNova, London, England) aortic valve (AV), which gained US Food and Drug Administration approval for commercial use in 2016. Implantation of the Perceval sutureless bioprosthetic AV by a median sternotomy or anterior thoracotomy and cardiopulmonary bypass (CPB) is different from conventional SAVR and requires intraoperative transesophageal echocardiographic (TEE) evaluation prior to separation from bypass to ensure appropriate placement. However, to date, there are few echocardiographic guidelines or recommendations available to direct anesthesiologists to perform a TEE assessment of the Perceval AV after implantation. The objective of this manuscript is to describe TEE parameters that may guide optimal
Journal of Cardiothoracic and Vascular Anesthesia | 2018
Adam A. Dalia; Antolin S. Flores; Hovig V. Chitilian; Michael G. Fitzsimons
Orthotopic liver transplantation (OLT) is characterized by significant hemodynamic disturbances and anesthetic challenges. Intraoperative transesophageal echocardiography (TEE) can be used to guide management during these procedures. This review examines the role of echocardiography during OLT, presents common TEE findings during each phase of OLT, and discusses the benefits demonstrated with TEE use and the safety of TEE in this patient population. Finally, the authors propose an algorithm for the safe use of TEE during OLT.
Journal of Cardiothoracic and Vascular Anesthesia | 2017
Adam A. Dalia; Daniel Bamira; Mazen Albaghdadi; Michael Essandoh; Kenneth Rosenfield; David M. Dudzinski
Journal of Cardiothoracic and Vascular Anesthesia | 2016
Michael Essandoh; Adam A. Dalia; Barry S. George; Antolin S. Flores; Andrew J. Otey; Ajay J. Kirtane; Thomas M. Broderick; Sunil V. Rao
Journal of Cardiothoracic and Vascular Anesthesia | 2018
Amy G. Fiedler; Adam A. Dalia; Andrea L. Axtell; Jamel P. Ortoleva; Sunu M. Thomas; Nathalie Roy; Mauricio A. Villavicencio; David A. D’Alessandro; Gaston Cudemus
Journal of Cardiothoracic and Vascular Anesthesia | 2018
Adam A. Dalia; Jamel P. Ortoleva; Amy G. Fiedler; Mauricio A. Villavicencio; Kenneth Shelton; Gaston Cudemus